Mechanism-of-Action Determination of GMP Synthase Inhibitors and Target Validation in Candida albicans and Aspergillus fumigatus

Chemistry and Biology

Volumn 14, Issue 10, 2007, Pages 1163-1175

  Rodriguez Suarez, Roberto ^a   Xu, Deming ^a   Veillette, Karynn ^a   Davison, John ^a   Sillaots, Susan ^a   Kauffman, Sarah ^b   Hu, Wenqi ^a   Bowman, Joel ^c   Martel, Nick ^a   Trosok, Steve ^a   Wang, Hao ^a   Zhang, Li ^a   Huang, Li Yin ^b   Li, Yang ^a   Rahkhoodaee, Fariba ^a   Ransom, Tara ^a   Gauvin, Daniel ^a   Douglas, Cameron ^c   Youngman, Phil ^c   Becker, Jeff ^b   Jiang, Bo ^a   Roemer, Terry ^a   more..

^a MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

^b UNIVERSITY OF TENNESSEE   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

CHEMBIO; SIGNALING

Indexed keywords

6 DIAZO 5 OXONORLEUCINE; ACIVICIN; ANTIFUNGAL AGENT; ENZYME INHIBITOR; GUANOSINE MONOPHOSPHATE SYNTHASE; INOSINATE DEHYDROGENASE; ISOXAZOLE DERIVATIVE; LIGASE; MIZORIBINE; MYCOPHENOLIC ACID; PURINE; PURINE DERIVATIVE; RIBONUCLEOSIDE; UNCLASSIFIED DRUG;

ANTIFUNGAL RESISTANCE; ARTICLE; ASPERGILLUS FUMIGATUS; CANDIDA ALBICANS; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; METABOLISM; MICROBIOLOGICAL EXAMINATION; POLYACRYLAMIDE GEL ELECTROPHORESIS; VALIDATION STUDY;

ANTIFUNGAL AGENTS; ASPERGILLUS FUMIGATUS; CANDIDA ALBICANS; CARBON-NITROGEN LIGASES; DIAZOOXONORLEUCINE; DRUG RESISTANCE, FUNGAL; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME INHIBITORS; IMP DEHYDROGENASE; ISOXAZOLES; MICROBIAL SENSITIVITY TESTS; MYCOPHENOLIC ACID; PURINES; RIBONUCLEOSIDES;

ASPERGILLUS FUMIGATUS; CANDIDA ALBICANS;

EID: 35348988264     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chembiol.2007.09.009     Document Type: Article

References (46)

1. Hughes T.R., Marton M.J., Jones A.R., Roberts C.J., Stoughton R., Armour C.D., Bennett H.A., Coffey E., Dai H., He Y.D., et al. Functional discovery via a compendium of expression profiles. Cell 102 (2000) 109-126
2. Michaud G.A., Samuels M.L., and Schweitzer B. Functional protein arrays to facilitate drug discovery and development. IDrugs 9 (2006) 266-272
3. Kley N., Ivanov I., and Meier-Ewert S. Genomics and proteomics tools for compound mode-of-action studies in drug discovery. Pharmacogenomics 5 (2004) 395-404
4. Bradner J.E., McPherson O.M., Mazitschek R., Barnes-Seeman D., Shen J.P., Dhaliwal J., Stevenson K.E., Duffner J.L., Park S.B., Neuberg D.S., et al. A robust small-molecule microarray platform for screening cell lysates. Chem. Biol. 13 (2006) 493-504
5. Duffner J.L., Clemons P.A., and Koehler A.N. A pipeline for ligand discovery using small-molecule microarrays. Curr. Opin. Chem. Biol. 11 (2007) 74-82
6. Boone C., Bussey H., and Andrews B.J. Exploring genetic interactions and networks with yeast. Nat. Rev. Genet. 8 (2007) 437-449
7. Lum P.Y., Armour C.D., Stepaniants S.B., Cavet G., Wolf M.K., Butler J.S., Hinshaw J.C., Garnier P., Prestwich G.D., Leonardson A., et al. Discovering modes of action for therapeutic compounds using a genome-wide screen of yeast heterozygotes. Cell 116 (2004) 121-137
8. Giaever G., Flaherty P., Kumm J., Proctor M., Nislow C., Jaramillo D.F., Chu A.M., Jordan M.I., Arkin A.P., and Davis R.W. Chemogenomic profiling: identifying the functional interactions of small molecules in yeast. Proc. Natl. Acad. Sci. USA 101 (2004) 793-798
9. Giaever G., Shoemaker D.D., Jones T.W., Liang H., Winzeler E.A., Astromoff A., and Davis R.W. Genomic profiling of drug sensitivities via induced haploinsufficiency. Nat. Genet. 21 (1999) 278-283
10. Baetz K., McHardy L., Gable K., Tarling T., Reberioux D., Bryan J., Andersen R.J., Dunn T., Hieter P., and Roberge M. Yeast genome-wide drug-induced haploinsufficiency screen to determine drug mode of action. Proc. Natl. Acad. Sci. USA 101 (2004) 4525-4530
11. Xu D., Jiang B., Ketela T., Lemieux S., Veillette K., Martel N., Davison J., Sillaots S., Trosok S., Bachewich C., et al. Genome-wide fitness test and mechanism-of-action studies of inhibitory compounds in Candida albicans. PLoS Pathog. 3 (2007) e92
12. Wisplinghoff H., Bischoff T., Tallent S.M., Seifert H., Wenzel R.P., and Edmond M.B. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis. 39 (2004) 309-317
13. Gudlaugsson O., Gillespie S., Lee K., Van de Berg J., Hu J., Messer S., Herwaldt L., Pfaller M., and Diekema D. Attributable mortality of nosocomial candidemia, revisited. Clin. Infect. Dis. 37 (2003) 1172-1177
14. Giaever G., Chu A.M., Ni L., Connelly C., Riles L., Veronneau S., Dow S., Lucau-Danila A., Anderson K., Andre B., et al. Functional profiling of the Saccharomyces cerevisiae genome. Nature 418 (2002) 387-391
15. Roemer T., Jiang B., Davison J., Ketela T., Veillette K., Breton A., Tandia F., Linteau A., Sillaots S., Marta C., et al. Large-scale essential gene identification in Candida albicans and applications to antifungal drug discovery. Mol. Microbiol. 50 (2003) 167-181
16. Perlroth J., Choi B., and Spellberg B. Nosocomial fungal infections: epidemiology, diagnosis, and treatment. Med. Mycol. 45 (2007) 321-346
17. Shaw R.J., Wilson J.L., Smith K.T., and Reines D. Regulation of an IMP dehydrogenase gene and its overexpression in drug-sensitive transcription elongation mutants of yeast. J. Biol. Chem. 276 (2001) 32905-32916
18. Desmoucelles C., Pinson B., Saint-Marc C., and Daignan-Fornier B. Screening the yeast "disruptome" for mutants affecting resistance to the immunosuppressive drug, mycophenolic acid. J. Biol. Chem. 277 (2002) 27036-27044
19. Kohler G.A., Gong X., Bentink S., Theiss S., Pagani G.M., Agabian N., and Hedstrom L. The functional basis of mycophenolic acid resistance in Candida albicans IMP dehydrogenase. J. Biol. Chem. 280 (2005) 11295-11302
20. Calabrese D., Bille J., and Sanglard D. A novel multidrug efflux transporter gene of the major facilitator superfamily from Candida albicans (FLU1) conferring resistance to fluconazole. Microbiology 146 (2000) 2743-2754
21. Yokota S. Mizoribine: mode of action and effects in clinical use. Pediatr. Int. 44 (2002) 196-198
22. Goudela S., Tsilivi H., and Diallinas G. Comparative kinetic analysis of AzgA and Fcy21p, prototypes of the two major fungal hypoxanthine-adenine-guanine transporter families. Mol. Membr. Biol. 23 (2006) 291-303
23. Tesmer J.J.G., Klem T.J., Deras M.L., Davisson V.J., and Smith J.L. The crystal structure of GMP synthase reveals a novel catalytic triad and is a structural paradigm for two enzyme families. Nat. Struct. Biol. 3 (1996) 74-86
24. Jayaram H.N., Cooney D.A., Ryan J.A., Neil G., Dion R.L., and Bono V.H. L-[alphaS, 5S]-alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid (NSC-163501): a new amino acid antibiotic with the properties of an antagonist of L-glutamine. Cancer Chemother. Rep. 59 (1975) 481-491
25. Ahluwalia G.S., Grem J.L., Hao Z., and Cooney D.A. Metabolism and action of amino acid analog anti-cancer agents. Pharmacol. Ther. 46 (1990) 243-271
26. Patel N., Moyed H.S., and Kane J.F. Properties of xanthosine 5′-monophosphate-amidotransferase from Escherichia coli. Arch. Biochem. Biophys. 178 (1977) 652-661
27. Nakamura J., Straub K., Wu J., and Lou L. The glutamine hydrolysis function of human GMP synthase. J. Biol. Chem. 270 (1995) 23450-23455
28. Zalkin H. The amidotransferases. Adv. Enzymol. Relat. Areas Mol. Biol. 66 (1993) 203-309
29. Lyons S.D., Sant M.E., and Christopherson R.I. Cytotoxic mechanisms of glutamine antagonists in mouse L1210 leukemia. J. Biol. Chem. 265 (1990) 11377-11381
30. Jong A., Yeh Y., and Ma J.J. Characteristics, substrate analysis, and intracellular location of Saccharomyces cerevisiae UMP kinase. Arch. Biochem. Biophys. 304 (1993) 197-204
31. Dujardin G., Kermorgant M., Slonimski P.P., and Boucherie H. Cloning and sequencing of the GMP synthetase-encoding gene of Saccharomyces cerevisiae. Gene 139 (1994) 127-132
32. Hu W., Sillaots S., Lemieux S., Davison J., Kauffman S., Breton A., Linteau A., Xin C., Bowman J., Becker J., et al. Essential gene identification and drug target prioritization in Aspergillus fumigatus. PLoS Pathog. 3 (2007) e24
33. Kirsch D.R., and Whitney R.R. Pathogenicity of Candida albicans auxotrophic mutants in experimental infections. Infect. Immun. 59 (1991) 3297-3300
34. D'Enfert C., Diaquin M., Delit A., Wuscher N., Debeaupuis J.P., Huerre M., and Latge J.-P. Attenuated virulence of uridine-uracil auxotrophs of Aspergillus fumigatus. Infect. Immun. 64 (1996) 4401-4405
35. Brown J.S., Aufauvre-Brown A., Brown J., Jennings J.M., Arst Jr. H., and Holden D.W. Signature-tagged and directed mutagenesis identify PABA synthetase as essential for Aspergillus fumigatus pathogenicity. Mol. Microbiol. 36 (2000) 1371-1380
36. Noble S.M., and Johnson A.D. Strains and strategies for large-scale gene deletion studies of the diploid human fungal pathogen Candida albicans. Eukaryot. Cell 4 (2005) 298-309
37. Ferreira M.E., Colombo A.L., Paulsen I., Ren Q., Wortman J., Huang J., Goldman M.H., and Goldman G.H. The ergosterol biosynthesis pathway, transporter genes, and azole resistance in Aspergillus fumigatus. Med. Mycol. 43 Suppl.1 (2005) S313-S319
38. Liu M., Healy M.D., Dougherty B.A., Esposito K.M., Maurice T.C., Mazzucco C.E., Bruccoleri R.E., Davison D.B., Frosco M., Barrett J.F., and Wang Y.K. Conserved fungal genes as potential targets for broad-spectrum antifungal drug discovery. Eukaryot. Cell 5 (2006) 638-649
39. Braun B.R., van Het Hoog M., d'Enfert C., Martchenko M., Dungan J., Kuo A., Inglis D.O., Uhl M.A., Hogues H., Berriman M., et al. A human-curated annotation of the Candida albicans genome. PLoS Genet. 1 (2005) 36-57
40. Beckerman J., Chibana H., Turner J., and Magee P.T. Single-copy IMH3 allele is sufficient to confer resistance to mycophenolic acid in Candida albicans and to mediate transformation of clinical Candida species. Infect. Immun. 69 (2001) 108-114
41. Payne D.J., Gwynn M.N., Holmes D.J., and Pompliano D.L. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat. Rev. Drug Discov. 6 (2007) 29-40
42. De Backer M.D., Nelissen B., Logghe M., Viaene J., Loonen I., Vandoninck S., de Hoogt R., Dewaele S., Simons F.A., Verhasselt P., et al. An antisense-based functional genomics approach for identification of genes critical for growth of Candida albicans. Nat. Biotechnol. 19 (2001) 235-241
43. Shimmura H., Tanabe K., Habiro K., Abe R., and Toma H. Combination effect of mycophenolate mofetil with mizoribine on cell proliferation assays and in a mouse heart transplantation model. Transplantation 82 (2006) 175-179
44. Loewen S.K., Ng A.M., Mohabir N.N., Baldwin S.A., Cass C.E., and Young J.D. Functional characterization of a H+/nucleoside co-transporter (CaCNT) from Candida albicans, a fungal member of the concentrative nucleoside transporter (CNT) family of membrane proteins. Yeast 20 (2003) 661-675
45. Kung C., Kenski D.M., Krukenberg K., Madhani H.D., and Shokat K.M. Selective kinase inhibition by exploiting differential pathway sensitivity. Chem. Biol. 13 (2006) 399-407
46. Bochner B.R., and Ames B.N. Complete analysis of cellular nucleotides by two-dimensional thin layer chromatography. J. Biol. Chem. 257 (1982) 9759-9769